• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » VisionCare launches new clinical trial for telescope implant

VisionCare launches new clinical trial for telescope implant

January 13, 2017 By Sarah Faulkner

VisionCare launches new clinical trial for telescope implantsVisionCare, Inc. said this week that the FDA approved its investigational device exemption for a new clinical trial in the U.S. evaluating its telescope implant in patients with end-stage macular degeneration.

The Saratoga, Calif.-based company’s implantable miniature telescope, which was developed by Israeli inventor Dr. Isaac Lipshitz, is contraindicated for patients with previous intraocular or corneal surgery of any kind. This new clinical trial will study the effectiveness of the telescope implant in patients who were previously implanted with an intraocular lens.

“The average patient, at least in North America, has their cataract surgery done between the ages of 68 and 72,” VisionCare president & CEO Blake Michaels said in a conversation with MassDevice.com. By the time the patient’s disease has progressed to the point of end-stage macular degeneration, they’ve most likely had cataract surgery and don’t qualify for the telescope implant because of the device’s contraindication, Michaels told us. “So it’s very frustrating for ophthalmologists and other vision professionals to see certain patients who would be perfect for the telescope but they’ve had cataract surgery in both eyes because they’re 78 years old and they have to tell them, ‘Sorry, we can’t operate on you.'”

The implant, which is smaller than a pea, is “an actual, Galilean telescope,” Michaels explained. It is implanted in 1 eye in an outpatient surgical procedure. The device enlarges images over a wide area of the retina to improve vision, while the non-operated eye provides peripheral vision.

VisionCare was approved to enroll 40 patients initially and collect 6 months of data, at which time the company can enroll another 10 patients. Michaels said the goal of the study is to demonstrate that the implant is safe and effective in this patient population and to move on to a pivotal trial, with the eventual goal of full approval for the indication.

The company has inked 1 contract with an undisclosed site and is actively looking for other sites within the U.S. to conduct the trial.

The telescope implant has won premarket approval from the FDA, the CE Mark in the European Union, and Health Canada listing. The implantable telescope is the only FDA approved surgical device for end-stage macular degeneration, according to VisionCare.

Filed Under: Clinical Trials, Implants, Optical/Ophthalmic, Surgical Tagged With: VisionCare Ophthalmic Technologies

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy